HLB: From Skyrocketing to Plunging

A Historic Achievement: Korea’s First Direct FDA Approval 🚀

“Ripictu,” a bile duct cancer treatment developed by HLB subsidiary Eleva, has received approval from the U.S. FDA, marking the first time in the history of Korea’s pharmaceutical and biotech industry that a new anticancer drug has achieved direct NDA approval.

Group Stocks Soar to Daily Limit Up 📈

Overcoming the setback of a request for supplemental data regarding a new liver cancer drug last July, the stock staged a dramatic comeback, causing not only HLB’s main stock but the entire group’s shares to surge to the daily price limit immediately after the market opened.

The Key Going Forward Is Actual Commercialization 💰

The drug is scheduled for launch in the U.S. in the fourth quarter of this year. Since it targets patients with specific genetic mutations, the expansion of actual prescriptions in the U.S. healthcare market and the generation of revenue will determine the stock’s future trajectory.

Translated with DeepL.com (free version)